Sinovac Biotech SVA
NASDAQ SVA
$6.47 +0.00 (+0.00%)
At close: Oct 28, 2026 · 4:00 PM EDT

Sinovac Biotech (SVA) Preferred Stock Liabilities (2023)

Updated

Sinovac Biotech's Preferred Stock Liabilities was $13.88 billion in Q4 2023.

Analysis

Sinovac Biotech (SVA) Preferred Stock Liabilities (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Sinovac Biotech 464.94 Mn -24.98 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 13.88 Bn
API Access

Sinovac Biotech Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=SVA&period=max&api_key=YOUR_API_KEY